TycelJovellePhillipsMD

PubMed

• 1 citations
  Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy.
  Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Loretta J Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy L Bartlett, Victoria R ...> ;Blood. 2024 Jan 22
• A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204).
  Avigdor, A., Gurion, R., Patti, C., Corradini, P., Tani, M., Mehta, A., Zinzani, P., Thieblemont, C., Jurczak, W., Zheng, F., Rappold, E., Zhao, W., Jiang, P., Phillip...> ;Blood Advances. 2024 Feb 27
• Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North Am...
  Barr, P. M., Barr, P. M., Julie M Vose, Kai Fu, Lu Wang, Adnan Mansoor, Douglas Stewart, Hongxia Cheng, Lynette Smith, Ji Yuan, Hina Naushad Qureishi, Brian K Link, Me...> ;Journal of Hematology & Oncology. 2023 Dec 16
• Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab.
  Tycel Phillips, Pieternella Lugtenburg, Anupama Kalsekar, Alex Mutebi, Anthony Wang, Julie Blaedel, Katherine Kosa, Susan Martin, Mariana Sacchi, Nurgul Kilavuz, Cathe...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Mar 1
• Estimated impact of ECHELON-1 overall survival on productivity costs in stage III/IV classical Hodgkin lymphoma in the United States.
  Tycel Phillips, Nicholas Liu, Brian Bloudek, Kristen Migliaccio-Walle, Jade Reynolds, John M Burke> ;Journal of Managed Care & Specialty Pharmacy. 2023 Dec 1
• Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis.
  Yuqin Song, Keshu Zhou, Dehui Zou, Dengju Li, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Daobin Zhou, Constantine ...> ;Cancer Medicine. 2023 Sep 1
• 3 citations
  Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.
  Adam J Olszewski, Tycel J Phillips, Marc S Hoffmann, Philippe Armand, Tae Min Kim, Dok Hyun Yoon, Amitkumar Mehta, Richard Greil, Jason Westin, Izidore S Lossos, Javie...> ;Blood Advances. 2023 Oct 24
• 2 citations
  T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia.
  Vi Lam, Carly Roleder, Tingting Liu, Scott Best, Xiaoguang Wang, Tycel Phillips, Geoffrey Shouse, Allison J Berger, Lapo Alinari, Lili Wang, Tanya Siddiqi, Nathan D Pe...> ;Molecular Cancer Therapeutics. 2023 Sep 5
• 3 citations
  COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma.
  Victoria R Nachar, Anthony J Perissinotti, Bernard L Marini, Yasmin H Karimi, Tycel J Phillips> ;Annals of Hematology. 2023 Sep 1
• 3 citations
  Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
  Andrew L Coveler, David C Smith, Tycel Phillips, Brendan D Curti, Sanjay Goel, Amitkumar N Mehta, Timothy M Kuzel, Svetomir N Markovic, Olivier Rixe, David L Bajor, Th...> ;Journal for Immunotherapy of Cancer. 2023 Jun 1
• TRES, a validated three-factor comorbidity score, is associated with survival in older patients with mantle cell lymphoma.
  Max J Gordon, David A Bond, Adam S Kittai, Neda Amirmokhtari, Abigail Steinbrunner, Allison Huffman, Victor Orellana-Noia, Geoffrey Shouse, Jonathon B Cohen, Tycel Phi...> ;Haematologica. 2023 Nov 1
• 2 citations
  Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial.
  Tycel Phillips, Kristen Migliaccio-Walle, Kristina S Yu, Brian Bloudek, Nicholas Liu, Michelle Fanale, John M Burke> ;Leukemia & Lymphoma. 2023 May 1
• 2 citations
  Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.
  Tycel J Phillips, David Bond, Radihka Takiar, Karson Kump, Malalthi Kandarpa, Philip Boonstra, Tera Lynn Mayer, Victoria Nachar, Ryan A Wilcox, Shannon A Carty, Yasmin...> ;Blood Advances. 2023 Aug 22
• 2 citations
  Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
  John M Burke, Nicholas Liu, Kristina S Yu, Michelle A Fanale, Andy Surinach, Carlos Flores, Julie Lisano, Tycel Phillips> ;The Oncologist. 2023 Jun 2
• 1 citations
  Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year...
  John M Burke, Kristina S Yu, Uche Mordi, Brian Bloudek, Nicholas Liu, Tycel Phillips> ;Journal of Managed Care & Specialty Pharmacy. 2023 Mar 1
• Durable responses with ALK inhibitors for primary refractory anaplastic lymphoma Kinase-positive large B-cell lymphoma.
  Radhika Takiar, Tycel J Phillips> ;Blood Advances. 2023 Jun 27
• 3 citations
  Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activity.
  Kang Le, Jing Sun, Javid Ghaemmaghami, Mitchell R Smith, W K Eddie Ip, Tycel Phillips, Mamta Gupta> ;Blood Advances. 2023 Aug 8
• 3 citations
  Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Pha...
  Elisabeth A Lasater, Dhara N Amin, Rajat Bannerji, Raghuveer Singh Mali, Kathy Barrett, Ryan N Rys, Jason Oeh, Eva Lin, Tim Sterne-Weiler, Ellen Rei Ingalla, MaryAnn G...> ;American Journal of Hematology. 2023 Mar 1
• 80 citations
  Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
  Catherine Thieblemont, Tycel Phillips, Herve Ghesquieres, Chan Y Cheah, Michael Roost Clausen, David Cunningham, Young Rok Do, Tatyana Feldman, Robin Gasiorowski, Wojc...> ;Journal of Clinical Oncology. 2023 Apr 20
• Divergent paths: management of early relapsed follicular lymphoma.
  Radhika Takiar, Yasmin Karimi, Tycel J Phillips> ;Hematology. American Society of Hematology. Education Program. 2022 Dec 9
• EXABS-204-MCL The Role of Targeted Therapies in Frontline Treatment of Mantle Cell Lymphoma.
  Radhika Takiar, Tycel J Phillips> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
• 4 citations
  Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas.
  Franck Morschhauser, Gilles Salles, Connie Lee Batlevi, Hervé Tilly, Aristeidis Chaidos, Tycel Phillips, John Burke, Ari Melnick> ;Blood Reviews. 2022 Nov 1
• 11 citations
  Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.
  Tycel Phillips, Henry Chan, Constantine S Tam, Alessandra Tedeschi, Patrick Johnston, Sung Yong Oh, Stephen Opat, Hyeon-Seok Eom, Heather Allewelt, Jennifer C Stern, Z...> ;Blood Advances. 2022 Jun 14
• 5 citations
  Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose?
  Henry Ngu, Radhika Takiar, Tycel Phillips, Jessica Okosun, Laurie H Sehn> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2022 Apr 1
• The physical exam's role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma.
  John S Runge, Anna B Brown, Tycel J Phillips, Mark S Kaminski, Shannon A Carty, Ryan A Wilcox> ;Journal of Oncology Pharmacy Practice. 2023 Apr 1
• Join now to see all

Abstracts/Posters

• Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-HodgkinÍs Lymphoma and C...
  Tycel J. Phillips, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and C...
  Tycel J. Phillips, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...
  Tycel J. Phillips, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Cen... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-) in Patients with Mantle Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all